Efthymios Deliargyris

Efthymios N. Deliargyris, MD, FACC, FESC, FSCAI

Dr. Efthymios “Makis” Deliargyris is triple board-certified in internal medicine, cardiology, and interventional cardiology with extensive industry experience. He is currently Chief Medical Officer at CytoSorbents Corporation. Prior to joining CytoSorbents, Dr. Deliargyris was CMO for PLx Pharma (NASDAQ: PLXP) and before that he was Global Medical Lead, Cardiovascular at The Medicines Company (NASDAQ: MDCO). Before joining industry, Dr. Deliargyris served as Director of Cardiology and Interventional Cardiology at Athens Medical Center in Greece and as Assistant Professor of Cardiology and Director of the Intravascular Ultrasound Laboratory at Wake Forest University Medical Center in Winston-Salem, North Carolina. Dr. Deliargyris’s original research on the role of inflammation in cardiovascular disease and in antithrombotic therapies has resulted in over 100 publications in top peer-reviewed journals including New England Journal of Medicine, Journal of the American College of Cardiology, Circulation, and the European Heart Journal and numerous awards, including the prestigious Society of Cardiac Angiography & Interventions (SCAI) Fellowship Award for best research in interventional cardiology. He received his MD from the Kapodistrian University School of Medicine in Athens, Greece, and completed his residency in internal medicine at Tufts University School of Medicine in Boston, where he also served as Chief Resident, and his fellowship in cardiology and interventional cardiology at the University of North Carolina at Chapel Hill, where he also served as Chief Fellow. Dr. Deliargyris is an elected Fellow of the American College of Cardiology (FACC), European Society of Cardiology (FESC) and Society for Cardiac Angiography and Interventions (FSCAI).